Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on February 28, 2020, 12:30:19 pm

Title: Saroglitazar Improves Liver Health in Those With Fatty Liver and NASH
Post by: Hep Editors on February 28, 2020, 12:30:19 pm
Saroglitazar magnesium improved various measures of liver health in a recent study of individuals with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Samer Gawrieh, MD, of Indiana University, presented findings from the prospective, multicenter, double-blind, Phase II randomized EVIDENCES IV trial of saroglitazar at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, in Boston this month.

Saroglitazar is a novel non-thiazolidinedione, non-fibric acid dual PPAR alpha-gamma agonist that plays a role in the oxidation of free fatty acids and reduces the production of triglycerides in the liver, thereby improving insulin sensitivity and glucose metabolism.

Read more...
https://www.hepmag.com/article/saroglitazar-improves-liver-health-fatty-liver-nash